UNSPSC 51332701: Batelapine

This classification denotes an antipsychotic agent with the molecular formula C16H20N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, P71TE299SG chemically known as 11h-(1,2,4)triazolo(1,5-c)(1,3)benzodiazepine, 2-methyl-5-(4-methyl-1-piperazinyl)- but generally known as batelapine, which bears US NIH Compound Identifier 60717. European Medicines Agency schedules Batelapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06110MIG.

UNSPSC 51332701 Batelapine is a Commodity code under which state and local governments procure pharmaceutical products, naloxone, drug deactivation systems, and over-the-counter medications through competitive and cooperative purchasing mechanisms. Recent opportunities reveal that this code captures procurement of emergency-response pharmaceuticals, opioid-antagonist products, and multi-source generic drugs distributed to public health agencies, county health departments, and state pharmacy benefit programs. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission and Minnesota Department of Administration appear as active buyers in the recent record.

Activity spans Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023 (the date appears inconsistent with the posting date; the solicitation requires electronic bid submission, E-Verify compliance, and fixed-fee pricing across an initial two-year term with one-year renewal option). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking market intelligence on direct contracting between state pharmacy programs and manufacturers outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026; the contract will be distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) and is valued on price competitiveness (75 percent weight), with a two-year term and optional extensions.